A recent study from Simple Divorce has uncovered a compelling connection between financial stress and increasing divorce ...

The Phase 2 randomized, double-blind, placebo-controlled clinical trial was conducted by Vincentage to investigate the ...

Sana is Incorporating the Tested Immune Evasion Technology to Develop SC451, a HIP-modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal ...

Mark Hahn also works closely with David Ebsworth, Chairman of Opterion Health, at Verona Pharma. Their ongoing collaboration ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to ...

The substantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseases SYDNEY, AUSTRALIA, June 23, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; ...

AnswersNow, the leader in virtual Applied Behavioral Analysis (ABA) therapy, today announced that Ernst & Young LLP (EY) has named its CEO Jeff Beck a 2025 Entrepreneur of the Year Mid-Atlantic Region ...

“I’m delighted to welcome Anne Marie Cook to Phathom. Her experience and broad skills will be highly impactful as we work to build Phathom into a leading GI company in the coming years,” said Steven ...

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies ...

KIRKLAND, Wash., June 23, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced that the company will be ...

MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and ...

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that it has submitted the clinical trial protocol ...